|Mr. Kurt B. Lemvigh||Chief Exec. Officer||N/A||N/A||49|
|Dr. Peter Phillips||Chief Technology Officer||292.1k||N/A||58|
|Ms. Linda D'Abate||VP of Global Clinical & Regulatory Affairs||123.16k||N/A||N/A|
|Andrew Debbage||VP of Operations||N/A||N/A||N/A|
|Mr. Jonathan Hornsby||VP of Sales & Marketing||N/A||N/A||N/A|
Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The companys principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.
Lombard Medical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.